Departing FDA chief will fight high drug prices in new post

After Scott Gottlieb, MD, steps down as commissioner of the FDA April 5, he will head back to the American Enterprise Institute to tackle the rising cost of prescription drugs, according to The Washington Post.

Advertisement

The 46-year-old physician, millionaire venture capitalist and cancer survivor plans to spend about a half-dozen days a month as a resident fellow at the conservative think tank. Before becoming FDA commissioner, Dr. Gottlieb wrote op-eds for the institute.

He announced in March he was leaving his position at the FDA to spend more time with his family. He had been commuting to Washington, D.C., from Connecticut weekly since his May 2017 appointment.

Beyond his work with the institute, Dr. Gottlieb plans to explore other opportunities, but “I don’t know what they are right now,” he told The Post.

More articles on pharmacy:
7 drugs projected to become blockbusters by 2023
3 insulin manufacturers to testify at House panel April 10
Cigna-Express Scripts cap out-of-pocket 30-day insulin costs at $25

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.